March 14, 2018 07:32 AM EDT
People
R&D
Pharma

Lousy year for share­hold­ers, but Al­ler­gan CEO Brent Saun­ders sprints past Gorsky, Gon­za­lez with $32M pay pack­age

John Carroll

Editor & Founder

Brent Saun­ders’ H2 2017 strat­e­gy to pre­serve con­trol of the Resta­sis patents may be un­der as­sault from every an­gle, forc­ing the com­pa­ny to re­struc­ture ahead …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times